Ryan G. Kruger

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

Michael T. McCabe, Heidi M. Ott, Gopinath Ganji et al. · Nature · 2012 · 1.8K citations

Medicine, Molecular Genetics, Oncology +15

The promise and peril of chemical probes

C.H. Arrowsmith, James E. Audia, Christopher P. Austin et al. · Nature Chemical Biology · 2015 · 850 citations · Full text

Natural Sciences, Chemistry, Medicinal Chemistry +12

EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation

Wendy Béguelin, Relja Popovic, Matt Teater et al. · Cancer Cell · 2013 · 841 citations · Full text

Life Sciences, Genetics, Molecular Biology +12

A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models

Elayne Chan-Penebre, Kristy G. Kuplast, Christina R. Majer et al. · Nature Chemical Biology · 2015 · 546 citations

Medicine, Medicinal Chemistry, Pharmacology +8

A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC

Helai P. Mohammad, Kimberly N. Smitheman, Chandrashekhar D. Kamat et al. · Cancer Cell · 2015 · 512 citations · Full text

Medicine, Molecular Biology, Oncology +12